Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Allergic Conjunctivitis Clinical Trial

Official title:

Multi-centre, Randomised, Double Blind, Placebo-controlled, Parallel, Phase III Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04810390
• Other study ID #: BOFT-0520/PED
• Status: Completed
• Phase: Phase 3
• Start date: March 26, 2021
• Est. completion date: November 30, 2022

Study information

• Verified date: July 2022
• Source: Faes Farma, S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of seasonal allergic conjunctivitis (SAC) or perennial allergic conjunctivitis (PAC).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: November 30, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria:

• 1. Male or female patients from 2 to under 18 years of age at V1a.

• 2. Documented history of AC before V1a.

• 3. Documented positive skin prick test and/or positive validated IgE test to seasonal (e.g. grass, ragweed, and/ or tree pollen) and/or perennial allergen (e.g. cat dander, dog dander, dust mites and/ or cockroach) within 6 months before V1a or a positive skin prick test at V1a.

• 4. Signs and symptoms of AC, i.e. tearing, itching and redness, that are likely to continue for the next weeks. Minimum score of four (in at least one eye) on an 11-item numeric rating scale in at least one of three categories at V1a.

• 5. Understanding of functioning and willingness to use e-diary at V1b and throughout study duration.

• 6. Willing to comply in all aspects of the study, including:

1. use of IMP from V1b to V5a

2. attending scheduled visits and completing telephone interviews.

• 7. Signed age-appropriate assent form (in participants 12 years of age and older) and written informed consent by the LAR in all cases. If a patient turns 18 years old during the clinical trial, a new written informed consent form will be provided and signed by the patient if he/she is willing to continue participating in the study.

• 8. Be able to self-administer eye drops satisfactorily or have a caregiver or LAR routinely available for this purpose. If a caregiver or LAR will be in charge of administering eye drops then he/she must attend Visit 1b, in order to be trained for administration of eye drops on-site.

• 9. For females of childbearing potential only: willingness to perform pregnancy tests, acceptance to use highly effective methods of birth control throughout the study duration. Highly effective methods of birth control include: combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner (provided that partner is the sole sexual partner of the clinical trial participant and has documentation of azoospermia) or sexual abstinence (if defined as refraining from heterosexual intercourse during the entire period of risk associated with the clinical trial treatment). The investigator is responsible for determining whether the subject has adequate birth control for study participation.

Exclusion Criteria:

• 1. History of known contraindications or sensitivities to the use of the IMPs or any of their components.

• 2. History of intraocular surgery within the previous 2 years before V1a, or planned surgery during study participation and within 2 weeks after follow-up.

• 3. History of ocular trauma (within the previous 6 months before V1a).

• 4. History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease within the previous year before V1a.

• 5. History of any clinically significant external ocular disease within 30 days before V1a.

• 6. Presence of dry eye, active blepharitis, active Meibomian gland dysfunction, active rosacea affecting the ocular surface/ lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect study outcome at V1a.

• 7. Known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye).

• 8. History of treatment failure to topical antihistamines.

• 9. Prior (within 2 years before V1a), current or anticipated anti-allergy immunotherapy.

• 10. Prior (within 4 weeks before V1a), current or anticipated corticosteroid treatment (systemic or local, in case of depot-corticosteroids: within 6 weeks before V1a).

• 11. Prior (within 1 week before V1a), current or anticipated use of any ophthalmic agents (including artificial tears), except IMPs (starting at V1b).

• 12. Wearing of contact lenses 24 hours before ophthalmologic tests (V1a) and during clinical trial participation until V6.

• 13. Prior (within 2 weeks before V1a), current or anticipated systemic or intranasal treatment for allergic rhinitis.

• 14. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.

• 15. Pregnant woman, breastfeeding woman or woman planning a pregnancy.

• 16. Body weight below the 5th percentile for their age (patients 10 years of age or younger only).

• 17. Patient has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before V1a or is currently enrolled in an investigational interventional study.

• 18. Any condition that, in the opinion of the investigator, may jeopardise the clinical trial conduct according to the protocol. (For example, evidence of diseases, medications or laboratory abnormalities that could alter the conduct of the study).

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Drug:
• Bilastine
Ophthalmic solution 0.6%
• Placebo
Ophthalmic solution

Locations

Country	Name	City	State
Spain	Instituto Oftálmologico Quironsalud A Coruña	A Coruña
Spain	Hospital Universitari German Trias i Pujol (HGTiP),	Badalona
Spain	Hospital Universitario de Cruces	Barakaldo	Bizkaia
Spain	Hospital Universitari Dexeus	Barcelona
Spain	Hospital Universitari Vall D'Hebron	Barcelona
Spain	Hospital General La Mancha Centro	Ciudad Real
Spain	Clínica Universidad de Navarra (CUN)- Sede Madrid	Madrid
Spain	Hospital Universitario Quirónsalud Madrid	Madrid
Spain	Hospital Quirónsalud Málaga	Málaga
Spain	Hospital Quirónsalud Marbella	Marbella
Spain	Hospital Universitario Central de Asturias	Oviedo
Spain	Clínica Juaneda	Palma De Mallorca
Spain	Clínica Universidad de Navarra	Pamplona
Spain	Hospital Universitario Donostia	San Sebastián
Spain	Hospital de Dia Quirónsalud Ave María	Sevilla
Spain	Hospital Quirón Valencia	Valencia
Spain	Hospital Universitario Dr. Peset Aleixandre	Valencia
Spain	Hospital Universitario Araba	Vitoria

Sponsors (2)

Lead Sponsor	Collaborator
Faes Farma, S.A.	Dynamic Science S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of related ocular treatment-emergent adverse events (ocular r-TEAEs)	It will be reported the incidence of related ocular treatment-emergent adverse events (ocular r-TEAEs) as primary safety endpoint.	8 weeks
Secondary	Incidence of treatment-emergent adverse events (TEAEs)	It will be reported the incidence of treatment-emergent adverse events (TEAEs)	8 weeks
Secondary	Incidence of ocular treatment-emergent adverse events (ocular TEAEs)	It will be reported the incidence of ocular treatment-emergent adverse events (ocular TEAEs)	8 weeks
Secondary	Incidence of related treatment-emergent adverse events (r-TEAEs)	It will be reported the incidence of related treatment-emergent adverse events (r-TEAEs)	8 weeks
Secondary	Incidence of abnormal clinical findings from ophthalmic examinations after instillation of IMP	It will be reported the incidence of abnormal clinical findings from ophthalmic examinations after instillation of IMP.; Ophthalmic examination will consist of: Best-corrected visual acuity test with age-appropriate techniques; Slit lamp biomicroscopy; Intraocular pressure in children who can cooperate with the test and do not require general anaesthesia; Non-dilated fundus examination	8 weeks
Secondary	Mean peak ocular discomfort score after on-site instillation of IMP	Potential peak ocular discomfort caused by IMPs will be evaluated separately for each eye by the patient, with the aid of LAR if required, immediately upon instillation, on an 11-item numeric rating scale (from 0 to 10), which will include age-appropriate visual scales for children.	8 weeks
Secondary	Mean ocular burning, stinging, tearing, blurring and stickiness scores after on-site instillation of IMP	Ocular tolerability (burning, stinging, tearing, blurring, and stickiness) of IMPs will be assessed separately for each eye by the patient with the aid of LAR if required,on an 11-item numeric rating scale (from 0 to 10), which will include age-appropriate visual scales for children.	8 weeks
Secondary	Absolute value as well as absolute and relative changes from baseline of average daily total eye symptoms score (TESS) over the entire 8-week treatment period	The total eye symptoms score (TESS) based on the patient's e-diary is defined as the sum of the ocular itching, redness, and tearing scores. For each patient the worst daily sum of ratings will be selected for analysis. Additional exploratory analyses will be performed for each ocular symptom using the mean results of both eyes.	8 weeks
Secondary	Absolute value as well as absolute and relative changes from baseline of average daily TESS at each week of the 8-week treatment period	The total eye symptoms score (TESS) based on the patient's e-diary is defined as the sum of the ocular itching, redness, and tearing scores. For each patient the worst daily sum of ratings will be selected for analysis. Additional exploratory analyses will be performed for each ocular symptom using the mean results of both eyes.	8 weeks
Secondary	Absolute value as well as absolute and relative changes from baseline of average daily itching, redness and tearing scores over the entire 8-week treatment period	The average value for both eyes in each single symptom score will be used.	8 weeks
Secondary	Absolute value as well as absolute and relative changes from baseline of average daily itching, redness and tearing scores at each week of the 8-week treatment period	The average value for both eyes in each single symptom score will be used.	8 weeks
Secondary	For seasonal allergic conjunctivitis (SAC) patients only, the average daily TESS over the 2-week period of peak total eye symptoms score	For SAC patients, the average daily TESS and single symptom scores over the 2-week period of peak TESS and the 2-week period of peak single symptom scores, respectively, will be analysed using ANOVA.	8 weeks
Secondary	For seasonal allergic conjunctivitis (SAC) patients only, the average daily itching, redness and tearing scores over the 2-week period of peak symptoms score	For SAC patients,the average daily itching, redness and tearing scores over the 2-week period of peak symptoms scores, respectively, will be analysed using ANOVA.	8 weeks